Infanrix-Ipv (Poliovirus (Inactivated) Type 3 (Saukett Strain), Pertussis Filamentous Haemagglutinin Adsorbed On A)

The vaccine contains inactivated poliovirus antigens and acellular pertussis components together with diphtheria and tetanus toxoids. After intramuscular injection, the antigens are taken up by antigen‑presenting cells, which stimulate B‑cells and T‑cells to produce specific antibodies and memory cells, establishing long‑lasting immunity against each pathogen.

The dosing schedule for Infanrix-Ipv is determined by national immunisation guidelines and the prescribing clinician. Typically, the vaccine is given as a series of intramuscular injections at specific ages in infancy, but the exact number of doses and timing are set by the health professional overseeing the child's vaccination plan.

Infanrix-Ipv is generally not administered to pregnant women because it is intended for infants. Breastfeeding mothers may receive the vaccine if indicated for their own protection, as the vaccine components are not known to be harmful to the infant. However, any vaccination during pregnancy or lactation should be discussed with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Infanrix-Ipv combines diphtheria, tetanus, acellular pertussis and inactivated poliovirus antigens in a single injection, reducing the number of separate shots required. Compared with separate monovalent vaccines, it simplifies the immunisation schedule and may improve compliance, while offering comparable safety and immunogenicity profiles as established in clinical studies.

Infanrix-Ipv must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Before administration, the vaccine should be allowed to reach room temperature for a short period, but any vial that appears cloudy or contains particles should be discarded.

The vaccine is supplied as an injectable suspension for intramuscular use. It is typically given into the anterolateral thigh muscle in infants or the deltoid muscle in older children, using a sterile needle and syringe. The injection should be performed by a qualified healthcare professional following aseptic technique.

Serious adverse events are rare but may include anaphylactic reactions, seizures, high fever, Guillain‑Barré syndrome, and encephalopathy. Immediate medical attention is required if signs of a severe allergic reaction (such as difficulty breathing, swelling of the face or throat) occur after vaccination.

Infanrix-Ipv should be avoided in individuals with a known severe allergy to any vaccine component, including the pertussis or poliovirus antigens. It is also contraindicated in persons who have experienced a severe reaction to a previous dose of the same vaccine. Consultation with a healthcare professional is essential for anyone with underlying medical conditions.